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Abstract
Background: Increasing evidence suggests that neutrophils play a role in the host response to Mycobacterium tuberculosis.
We determined whether neutrophil counts in peripheral blood are associated with tuberculosis (TB) and with mycobacterial
load in sputum in HIV-infected patients.
Methodology/Principal Findings: Adults enrolling in an antiretroviral treatment (ART) clinic in a Cape Town township were
screened for TB regardless of symptoms. Paired sputum samples were examined using liquid culture, fluorescence
microscopy, and the Xpert MTB/RIF assay. Absolute neutrophil counts (ANC) were measured in blood samples. Of 602 HIV-
infected patients screened, 523 produced one or more sputum samples and had complete results available for analysis.
Among these 523 patients, the median CD4 count was 1696109/L (IQR, 96–232) and median ANC was 2.66109/L (IQR, 1.9–
3.6). Culture-positive pulmonary tuberculosis was diagnosed in 89 patients. Patients with TB had a median ANC of 3.46109/L
(IQR, 2.4–5.1) compared to 2.56109/L (IQR, 1.8–3.4) among those who were culture negative (p,0.0001). In multivariable
analyses, having pulmonary TB was associated with an adjusted risk ratio (aRR) of 2.6 (95%CI, 1.5–4.5) for having an ANC
level that exceeded the median value (ANC $2.66109/L; p = 0.0006) and an aRR of 6.8 (95%CI, 2.3–20.4) for having
neutrophilia defined by a neutrophil count exceeding the upper limit of the normal range (ANC .7.56109/L; p = 0.0005).
Patients were then classified into four mutually exclusive groups with increasing sputum mycobacterial load as defined by
the results of culture, Xpert MTB/RIF and sputum smear microscopy. Multivariable analyses demonstrated that increasing
sputum mycobacterial load was positively associated with blood ANC $2.66109/L and with neutrophilia.
Conclusions/Significance: Increased blood neutrophil counts were independently associated with pulmonary TB and
sputum mycobacterial burden in this HIV-infected patient group. This observation supports the growing body of literature
regarding the potential role for neutrophils in the host response to TB.
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Introduction
The host response to Mycobacterium tuberculosis (MTB) is complex
and incompletely understood. While this response is thought to be
predominantly mediated by mononuclear leukocytes, evidence has
emerged in recent years suggesting that neutrophils may also play
a role [1]. It is known that neutrophils are the most commonly
infected phagocytic cell in sputum samples in the airways of
patients with active tuberculosis (TB) [1,2]. In a study of direct
contacts of patients with proven TB-disease, the risk of TB
infection was inversely related to the peripheral blood neutrophil
count [3]. Neutrophils appear to not only have a phagocytic role,
but they also produce antimicrobial peptides such as cathelicidin
LL-37, which has immunomodulatory functions as well as direct
activity against MTB [3,4]. Collectively, these findings suggest that
neutrophils may play an important role as part of the innate host
response to mycobacteria and contribute to the early control of
MTB infection. Conversely, however, in patients with established
TB disease, higher peripheral neutrophil counts are associated
with delayed mycobacterial clearance from sputum [5] and worse
clinical prognosis [6,7]. Thus, neutrophils may have conflicting
roles in the response to MTB that may be related to both
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mycobacterium-specific and host-specific factors as well as the
stage of clinical disease.
In previous studies of new diagnostic assays for HIV-associated
TB, we have noticed that there may be an association between
HIV-associated TB and increased blood neutrophil counts [8–11].
We therefore undertook this careful analysis to determine whether
such an association exists. Patients were also categorized into four
mutually exclusive groups, reflecting differing sputum mycobac-
terial burden, to further explore a possible association with sputum
bacillary burden using multivariable analyses to control for
potentially confounding variables.
Methods
Patient Characteristics
The community-based antiretroviral therapy (ART) service in
Gugulethu township in Cape Town, South Africa and the burden
of TB among its patients have been previously described in detail
[12–15]. Eligible HIV-infected patients were consecutively
recruited from patients newly referred to the clinic for ART
initiation. Eligible patients were aged $18 years, ART-naı¨ve and
did not have a current TB diagnosis. All patients received
trimethoprim-sulphamethoxazole prophylaxis. All patients provid-
ed written informed consent and the study was approved by the
research ethics committees of the University of Cape Town and
the London School of Hygiene & Tropical Medicine, UK.
Upon their first visit to the clinic, patients had demographic
details recorded, a standardized symptom-screening questionnaire
[16] was completed and clinical samples were obtained. Two
sputum samples were obtained whenever possible, with at least
one sample being induced using nebulised hypertonic saline [17].
Urine samples were collected in sterile containers and were stored
at 220uC within 3 hours of specimen collection. EDTA-
anticoagulated venous blood samples were obtained. Flow
cytometry (Becton Dickinson, Franklin lakes, New Jersey, USA)
was used to measure blood CD4 cell counts and plasma viral load
was measured using branched DNA technology (Bayer Diagnos-
tics, Tarrytown, New York, USA). Blood absolute neutrophil
counts were determined using ADVIA 2120 hematology analyzer
(Siemens Healthcare Diagnostics, Erlangen, Germany). The
National Health Laboratory Service (NHLS) of South Africa
performed all blood tests.
Laboratory Procedures
Sputum samples were processed in an accredited laboratory. N-
acetyl-L-cysteine and sodium hydroxide were used to decontam-
inate samples, which were then concentrated by centrifugation.
Prepared smears were stained with auramine O fluorescent stain
for fluorescence microscopy. ‘Smear-positive’ was defined as any
smear graded as scanty, 1+, 2+ or 3+. The remaining sputum
pellet was then tested by Xpert MTB/RIF assay and liquid culture
using Mycobacterial Growth Indicator Tubes (MGIT, Becton
Dickinson, Sparks, Maryland, USA). MTBDRplus assay (Hain
Lifesciences, Nehren, Germany) was used to identify culture
isolates as MTB. Frozen urine samples were defrosted and
analysed for the presence of lipoarabinomannan (LAM) using
the Clearview TB ELISA (Alere, Waltham, MA, USA) according
to manufacturer’s instructions.
The concentrations of gram-negative bacterial endotoxin were
measured in blood samples using Limulus Amebocyte Lysate
(LAL) QCL-1000 assay (Lonza,Walkersville, MD, USA) via the
microplate method. Blood samples were first defrosted to ambient
temperature. The microplate was pre-equilibrated to 37uC and
50 ml of serum was added to each microplate well. At the start of
the assay, 50 ml of LAL was added to each microplate well and the
samples were briefly mixed and incubated for 10 minutes. Next,
100 ml of substrate solution was added to each of wells and they
were again briefly mixed and incubated for an additional 6
minutes. After 16 total minutes 100 ml of the stop reagent was
added to the wells and the absorbance of each well was read at
410 nm.
Figure 1. Flow diagram showing patients included in the analysis.
doi:10.1371/journal.pone.0067956.g001
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Definitions and Analysis
A confirmed TB case was defined by MTB cultured from one or
more sputum sample. In addition, TB cases were categorised
according to sputum mycobacterial burden as defined by the
results of TB assays on sputum samples: Xpert-negative/smear-negative
(low mycobacterial burden), Xpert-positive/smear-negative (intermedi-
ate mycobacterial burden) and Xpert-positive/smear-positive (high
mycobacterial burden). The normal ANC range was 2.0–
7.56109/L and was based upon NHLS reference ranges.
Neutrophilia was defined as an ANC .7.56109/L, the upper
limit of the normal reference range.
We compared medians between two groups using Wilcoxon
rank-sum tests; the medians among three or more groups were
compared using Kruskal-Wallis tests. Proportions were compared
using either chi-squared tests or Fisher’s exact tests as indicated by
sample size. Logistic regression analyses were used to identify
factors independently associated with culture-confirmed TB and
different levels of sputum mycobacterial load. A priori it was
determined that continuous variables would be re-coded into
categorical variables, either according to approximate median
values or clinically logical cut-off points. All variables in the
univariable model meeting a cut-off of p#0.1 were included in the
multivariable model. Statistical tests were 2-sided at a= 0.05.
Results
Tuberculosis Diagnoses
Of 602 patients recruited, 542 (90.0%) produced at least one
sputum sample and complete culture and Xpert MTB/RIF results
were available for 523 (86.9%) (Figure 1). The median CD4
count among those in the cohort (n = 523) was 169 cells/uL (IQR,
96–232). A total of 89 culture-positive pulmonary TB cases were
diagnosed (17.0% prevalence [95% CI, 13.9–20.5]) and 431
patients had negative sputum cultures.
Confirmed TB cases were predominantly female, had a median
age of 33.4 years (IQR, 28.3–40.4), and a median body mass index
(BMI) of 21.2 kg/m2 (IQR, 19.2–25.0) (Table 1). Additionally,
TB cases had a median CD4 cell count of 131 cells/uL (IQR, 55–
204), a median plasma viral load of 4.8 log10 copies/mL (IQR,
4.4–5.3) and 72 (82.0%) had a positive WHO symptom screen.
The median time to culture-positivity was 16 days (IQR, 11–21).
Compared to patients with negative sputum cultures, TB cases
had lower body mass index (BMI), hemoglobin concentration,
platelet count and CD4 cell count (Table 1). TB cases also had
higher viral loads and were more likely to have a positive WHO
symptom screen and pulmonary radiographic abnormalities.
Blood endotoxin levels were similar in those with and without
pulmonary TB.
Neutrophil Counts in Patients with and without
Pulmonary TB
The median ANC among the total cohort (n = 523) was
2.66109/L (IQR, 1.9–3.6). However, those with TB had higher
blood ANC than those without TB (Figure 2a), with median
counts of 3.46109/L (IQR, 2.4–5.1) compared to 2.56109/L
(IQR, 1.8–3.4) (p,0.001). Furthermore, 15.3% (95%CI 8.4–24.7)
of patients with pulmonary TB had neutrophilia compared to
1.7% (95%CI 0.7–3.5) among those without pulmonary TB
(p,0.001).
In multivariable analyses (Table 2), strong associations were
observed between culture-confirmed TB and lower blood hemo-
globin concentration. Culture-confirmed TB was strongly associ-
ated with an ANC greater than the median value and with
neutrophilia. Among patients with pulmonary TB, the adjusted
risk ratio (aRR) for an ANC above median value was 2.6 (95%CI,
1.5–4.5) compared to those without pulmonary TB (p = 0.0006).
Furthermore, among patients with pulmonary TB, the aRR for
neutrophilia was 6.8 (95%CI, 2.3–20.4) compared to those without
pulmonary TB (p = 0.0005).
Characteristics of Patients Grouped by Sputum
Mycobacterial Load
Among those with culture-confirmed TB (n = 89), 25 (28.1%)
had a low sputum mycobacterial burden (Xpert-negative/smear-
negative), 40 (44.9%) had an intermediate sputum mycobacterial
burden (Xpert-positive/smear-negative) and 24 (27.0%) had a high
sputum mycobacterial burden (Xpert-positive/smear-positive). The
median times to positive culture for patients classified as having
low, intermediate and high sputum mycobacterial burden were 21
Figure 2. Box and whisker diagram of absolute neutrophil
count among those (a) with and without pulmonary TB and (b)
and among those with increasing levels of sputum mycobac-
terial load. The middle of the box represents the median value and
the outer box edges represent the 25th and 75th percentiles (IQR). The
ends of the whiskers represent the lower and upper adjacent values.
Outliers as defined by any data point above the upper adjacent value,
were excluded from both plots. The dashed line at ANC= 7.56109/L
represents the upper limit of the normal ANC range, above which is
considered neutrophilia.
doi:10.1371/journal.pone.0067956.g002
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days (IQR, 17–25), 16 days (IQR, 13–20.5) and 9.5 days (IQR, 8–
12), respectively (p = 0.0001).
Patients with higher levels of sputum mycobacterial burden had
lower BMI, lower hemoglobin concentrations, lower CD4 cell
counts and higher viral loads (Table 1). Additionally, as the
mycobacterial burden among patients increased, so too did the
proportion of those with a positive WHO symptom screen,
positive LAM ELISA result and those with a radiological
abnormality on chest X-ray.
Neutrophil Counts in Patients Grouped by Sputum
Mycobacterial Load
Blood neutrophil counts were higher in those with greater
sputum mycobacterial burden (Figure 2b); those who were
culture-negative or who had low, intermediate or high mycobac-
terial burdens had corresponding median ANC values of
2.56109/L (IQR, 1.8–3.4), 2.96109/L (IQR, 2.4–6.2), 3.36109/
L (IQR, 2.4–6.2) and 4.46109/L (IQR, 3.3–7.9), respectively
(p = 0.0001). The proportion of patients with neutrophilia also
increased with increasing sputum mycobacterial load (Figure 3),
and nearly 30% of patients with high sputum mycobacterial
burden had neutrophilia (p,0.001).
Table 2. Univariable and multivariable logistical regression of risk factors associated with pulmonary TB.
Analysis #1 (using ANC above
median value) Analysis #2 (using neutrophilia)
Risk factor Unadjusted RR (95%CI) P-value Adjusted RR (95%CI) P-value Adjusted RR (95%CI) P-value
BMI (kg/m2)
.25 1.0 – 1.0 – 1.0 –
18–25 1.67 (0.98–2.85) 0.0019 1.44 (0.80–2.61) 0.1788 1.50 (0.82–2.75) 0.1689
,18 4.49 (1.98–10.16) 2.39 (0.93–6.15) 2.40 (0.92–6.22)
Haemoglobin (g/dL)
.12 1.0 – 1.0 – 1.0 –
8–12 2.96 (1.74–5.05) ,0.0001 2.52 (1.42–4.48) 0.0004 2.76 (1.55–4.92) 0.0004
,8 7.83 (3.27–18.72) 5.32 (2.0–14.16) 4.44 (1.60–12.33)
Absolute neutrophil count
(6109/L)
,2.6 1.0 – 1.0 –
$2.6 2.76 (1.67–4.55) ,0.0001 2.57 (1.48–4.47) 0.0006
Neutrophilia (ANC .7.56109/L)
No 1.0 – 1.0 –
Yes 10.21 (3.94–26.48) ,0.0001 6.81 (2.28–20.38) 0.0005
ALT (IU/L)
,20 1.0 –
$20 1.33 (0.83–2.13) 0.2341
Platelets (platelets/uL)
,266 1.0 – 1.0 1.0
$266 1.63 (1.01–2.63) 0.0400 0.92 (0.54–1.59) 0.7670 0.98 (0.58–1.68) 0.9500
Endotoxin (EU/mL)
,0.7 1.0 –
$0.7 0.83 (0.51–1.32) 0.4228
CD4 cell counts (cells/uL)
CD4$200 1.0 – 1.0 – 1.0 –
CD4 150–199 1.01 (0.49–2.08) 0.0178 0.74 (0.33–1.67) 0.3784 0.72 (0.32–1.62) 0.5405
CD4 100–149 1.49 (0.76–2.93) 1.07 (0.50–2.30) 0.90 (0.42–1.94)
CD4 50–99 1.83 (0.88–3.78) 1.59 (0.71–3.56) 1.25 (0.56–2.81)
CD4,50 3.00 (1.53–5.92) 1.63 (0.74–3.60) 1.52 (0.68–3.38)
Log viral load (log copies/mL)
,4.5 1.0 – 1.0 – 1.0 –
$4.5 2.57 (1.56–4.23) 0.0001 1.62 (0.92–2.86) 0.0889 1.70 (0.97–2.99) 0.0632
WHO stage
1 or 2 1.0 – 1.0 – 1.0 –
3 or 4 1.98 (1.25–3.15) 0.0041 1.23 (0.69–2.18) 0.4903 1.02 (0.57–1.86) 0.9356
doi:10.1371/journal.pone.0067956.t002
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In univariable analyses, sputum mycobacterial load was
associated with a large number of variables (using a cutoff of
p = 0.1), including an ANC greater than the median value and
neutrophilia (Table S1a). In multivariable analyses, the relation-
ship between increasing mycobacterial load and an ANC above
median value and neutrophilia persisted (Tables S1b and S1c).
The fully adjusted risk ratios for an ANC greater than the median
Figure 3. The proportion (with 95% confidence intervals) of patients with HIV-associated TB who have neutrophilia, stratified by
increasing level of sputum mycobacterial load.
doi:10.1371/journal.pone.0067956.g003
Figure 4. Log adjusted risk ratios (aRR) for increased blood neutrophil counts stratified by low (n=25), intermediate (n=40) and
high (n=24) sputum mycobacterial load.
doi:10.1371/journal.pone.0067956.g004
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value and neutrophilia are displayed in Figure 4 and reveal a
strongly positive relationship with increasing mycobacterial load.
Discussion
Some evidence suggests that neutrophils play a role in both
early TB infection and late TB disease although the specific roles
in host responses and TB pathology remain incompletely defined.
In this study, we found that pulmonary TB disease was
independently associated with increased blood neutrophil counts
(both an ANC greater than the median value and neutrophilia)
and that these parameters were positively associated with sputum
mycobacterial load.
The strength of the positive association observed between
sputum mycobacterial burden and blood neutrophil counts was
particularly striking. This relationship persisted after controlling
for important confounding factors including CD4 cell counts.
While CD4 cell count was associated with both pulmonary TB
and sputum mycobacterial burden in the univariable analyses,
these associations did not persist in multivariable analyses.
Additionally, we accounted for translocation of gram-negative
bacteria and bacterial products from the gastrointestinal tract by
measuring endotoxin levels in serum samples. While sputum
mycobacterial load levels were independently associated with
blood endotoxin levels, there was no clear positive or negative
correlation observed between these variables. Since all patients
received trimethoprim-sulphamethoxazole prophylaxis, the risk of
sepsis as a confounder of increased blood neutrophil counts is
further reduced. Having examined for confounding associated
with these key variables increases the robustness of our findings.
The results of sputum TB assays were used to categorise patients
into four mutually exclusive groups, differing in sputum myco-
bacterial load. MGIT liquid culture, Xpert MTB/RIF and AFB
microscopy all have well described lower limits of detection for
MTB [18] and so their results were used in combination to stratify
patients. Use of these categories was supported by the finding that
higher mycobacterial load groups had shorter times to sputum
culture positivity and increased likelihood of positive urine LAM
results (two indirect markers that are likely to reflect mycobacterial
load). Increasing sputum mycobacterial burden is indicative of
poorly controlled pulmonary mycobacterial replication and this
was found to be associated with increased neutrophil counts in
peripheral blood.
We do not know whether increased neutrophil counts resulted
from an increase in absolute numbers of neutrophils in the body or
from trafficking of neutrophils into the blood compartment.
Increased neutrophil counts are common among patients with
active-TB disease in the context of a poorly functioning acquired
immune response [1]. While granuloma formation typically
involves the interaction of macrophages and lymphocytes,
neutrophils are also observed at the site of active mycobacterial
disease [2,19,20]. Having high peripheral neutrophil counts may
be prognostic, where increased blood levels are not only associated
with slow clearance of TB bacilli from sputum [5] but also an
increased risk of death [6,7].
Increased blood neutrophil counts in patients with HIV-
associated pulmonary TB may be attributable to a number of
possible mechanisms [1]. The first includes an immunological loss
of control of inflammation, thus allowing for the uncontrolled
influx of neutrophils to the site of disease [21] with mobilisation
from bone marrow secondary to high circulating levels of
inflammatory mediators. For example, patients with active TB
have higher circulating levels of IL-8 [22], which drives neutrophil
mobilization [23], IL-6, which drives neutrophil granulopoiesis
[24], and G-CSF, which performs both of these functions.
Systemic activation of the complement cascade, and probably
the presence of mycobacterial products in the circulation, would
also directly lead to release of neutrophils from marrow stores.
Furthermore, during established TB disease in mice, interferon-
gamma (IFN-c) 2/2 memory CD4+ cells retain antimicrobial
activity, but are unable to suppress inflammation and IL-17
production [21]. Because IL-17 can regulate neutrophil mobilisa-
tion during MTB infection, high blood neutrophil counts may be
observed in patients with advanced TB disease.
Inherent dysfunction of neutrophils in patients with TB may
also result in increased blood neutrophil counts. Dysfunctional
neutrophils may result in a decreased ability to kill mycobacteria,
leading to a non-specific inflammatory cascade, cytokine produc-
tion or excess necrotic cell death; any or all of which could
continue to drive neutrophil accumulation via consequent systemic
inflammation [1]. While data are conflicting, in patients with
pulmonary TB with and without concomitant HIV-infection,
neutrophils may have impaired ability to phagocytose TB bacilli
and to undergo oxidative burst [25–27].
Finally, neutrophilic ‘compensation’ for an inadequate mono-
nuclear and acquired immune response secondary to advanced
HIV disease may also cause increased neutrophil counts periph-
erally [1]. However, it is not known whether some or all of the
mechanisms outlined above contributed to our observation of an
ANC greater than the median value and neutrophilia in those with
HIV-associated pulmonary TB, as this is beyond the scope of this
study. It is also unclear whether the role of neutrophils in host-
specific mycobacterial responses is greatly altered in the context of
HIV-disease as few studies have investigated this question.
Strengths of this study include a well-characterized, consecu-
tively recruited cohort of patients similar to others in Southern
Africa enrolling in ART services, where all pulmonary TB
diagnoses were made using a culture-based reference standard.
While we have attempted to account for various potential
confounding variables including sepsis, residual confounding
may still be present. Additionally, while several correlates of
mycobacterial burden were assessed, patient sputum MTB
burdens were not directly quantified using colony counts. Finally,
as this is an observational study, only associations can be reported
and immunological mechanisms cannot be explored.
In conclusion, increased blood neutrophil counts were observed
in patients with HIV-associated pulmonary TB. Sputum myco-
bacterial burden was independently associated with an ANC
greater than the median value and neutrophilia, where those with
a high sputum mycobacterial burden were at greatest risk for
having increased blood neutrophil counts. This observation
supports the growing body of literature regarding the potential
role for neutrophils in the host response to TB and HIV-associated
TB. Further studies will be needed to examine these findings in
different clinical settings. A greater understanding of the role of
neutrophils in the context of TB disease with and without
concomitant HIV-disease is needed.
Supporting Information
Table S1 Logistic regression analyses showing the association
between patient characteristics and unadjusted and adjusted risk
ratios of varying levels of sputum mycobacterial burden among
those with pulmonary TB, where (a) is a univariable, multinomial
logistic regression with unadjusted risk ratios (b) is a multivariable,
multinomial logistic regression with adjusted risk ratios (aRR)
where the analysis includes an ANC greater than the median value
(ANC $2.66109/L) as a potential risk factor and (c) is a
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multivariable, multinomial logistic with aRR where the analysis
includes neutrophilia (ANC .7.56109/L) as a potential risk
factor.
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